Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium - Seite 2

His views were shared by Mr Paul Hayes, Vascular Surgeon at Addenbrooke's Hospital, who explained that VLUs consume 10-20% of vascular surgery clinic time, while great resources were also being spent on treating Britain's some 100,000 DFU patients¹. Mr Hayes said it was much cheaper to treat patients as an out-patient, which was one of the attractions to ReGenerCell™.

"If acute wounds are referred into secondary care earlier, we could actually stop them from being so difficult to treat," Mr Hayes commented. "With the exception of diabetic foot ulcers, chronic wounds have not become headline-grabbing conditions. So we need to have a group of interested individuals who can be dedicated to the cause."

Dr Nik Georgopoulos, Senior Lecturer, Department of Biological Sciences at the University of Huddersfield, supported Mr Hayes call for action, saying, "By supporting the way the device operates with biological evidence we are able to give more confidence to the clinicians who use it on its efficacy. The economic burden of chronic wounds is not in the range of the millions (of pounds), it's in the range of billions."

Adam Kelliher, CEO of Avita Medical, concluded: "Regenerative medicine and using the body's own healing responses is becoming more widespread in medical practice. The body of data supporting the efficacy of our devices is growing every day. Whilst mainstream adoption of new technologies rightly takes time, the clinicians pioneering our technology agree that barriers to widespread uptake need to be overcome. The use of Avita's technology positively impacts patients with quicker and more significant wound healing, less inconvenience and much less pain."

Indicators have shown Avita's technology also saves money for healthcare services when replacing or combined with traditional methods, the Company says. It will be gathering important pharmaco-economic data during its ongoing clinical studies, to support adoption of its products.

With data collected from over 6,000 procedures worldwide, Avita's patented technology is CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use.

¹ https://www.diabetes.org.uk/FactsandStats

ABOUT AVITA MEDICAL LTD
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION

Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: [phone]
[e-mail]

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 [phone]
[e-mail]

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone [phone]
[e-mail]

UK/EU
Instinctif Partners
Gemma Howe/Sue Charles
Phone [phone]
[e-mail]

USA
The Ruth Group
David Burke
Investor Relations
Kirsten Thomas
Public Relations
Phone: [phone]
[e-mail] / [e-mail]

Australia
Monsoon Communications
Dean Felton
Investor Relations / PR
Phone: [phone]
Mobile: [phone]
[e-mail]